DEERFIELD, Ill.--(BUSINESS WIRE)--TerSera Therapeutics LLC announced today the presentation of new real-world analyses on the treatment patterns of goserelin in women with breast cancer. The data were ...
Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...
WASHINGTON, May 30 (UPI) --The drug goserelin, sold by AstraZeneca under the brand name Zoladex, may help protect the ovaries of women with breast cancer. "It's not a panacea, but based on these data, ...
DEERFIELD, Ill.-- (BUSINESS WIRE)--TerSera Therapeutics LLC announced today that The National Comprehensive Cancer Network® (NCCN) Breast Cancer Panel included both goserelin 3.6 mg every 4 weeks and ...
UCHealth is slicing the cost of a cancer drug after acknowledging it had been overcharging patients and insurance companies for years. The move, following a Coloradoan investigation into the health ...
Goserelin (as acetate) 10.8mg; SC implant. Zoladex is a synthetic decapeptide analogue of GnRH. It acts as an inhibitor of pituitary gonadotropin secretion when administered in the biodegradable ...
Final results of a clinical trial show continued evidence that women who get injections of the hormone drug goserelin along with standard breast cancer chemotherapy are more likely to become pregnant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results